@AnnSurgOncol @McMastersKelly @SocSurgOnc Neoadjuvant chemotherapy is a useful strategy to improve rates of breast conservation. Tools to help predict which patients are suitable candidates can encourage appropriate use. https://t.co/VzWHQ2D7b4
@CarlaFisherMD I am doing it and I’m listening to a talk about it to a full house at ACS right now.
RT @BIDMCSurgery: Research by Dr. Ted A. James @BIDMCbreastsurg et al published in Feb. Annals of Surgical Oncology suggests #Oncotype DX t…
Who is using this test to determine use of NAC? Is it ready for prime time? #bcsm Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy | SpringerLink https://t.co/8PlpTlOE6H
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @DrTedJames: Congratulations to @BIDMCSurgery resident @AlisonMPease21 for her recent publication on #breastcancer genomics. @AnnSurgOnc…
RT @DrTedJames: Congratulations to @BIDMCSurgery resident @AlisonMPease21 for her recent publication on #breastcancer genomics. @AnnSurgOnc…
RT @DrTedJames: Congratulations to @BIDMCSurgery resident @AlisonMPease21 for her recent publication on #breastcancer genomics. @AnnSurgOnc…
RT @DrTedJames: Congratulations to @BIDMCSurgery resident @AlisonMPease21 for her recent publication on #breastcancer genomics. @AnnSurgOnc…
RT @DrTedJames: Congratulations to @BIDMCSurgery resident @AlisonMPease21 for her recent publication on #breastcancer genomics. @AnnSurgOnc…
Congratulations to @BIDMCSurgery resident @AlisonMPease21 for her recent publication on #breastcancer genomics. @AnnSurgOncol #clinicalresearch https://t.co/0ImHwmMc9J
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @BIDMCbreastsurg: We found that Oncotype DX testing could help identify patients best suited for neoadjuvant chemotherapy. @AnnSurgOnco…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @BIDMCSurgery: Research by Dr. Ted A. James @BIDMCbreastsurg et al published in Feb. Annals of Surgical Oncology suggests #Oncotype DX t…
RT @BIDMCSurgery: Research by Dr. Ted A. James @BIDMCbreastsurg et al published in Feb. Annals of Surgical Oncology suggests #Oncotype DX t…
RT @BIDMCSurgery: Research by Dr. Ted A. James @BIDMCbreastsurg et al published in Feb. Annals of Surgical Oncology suggests #Oncotype DX t…
RT @ElizaJaneLee: Congrats! Proud of you @AlisonMPease21!!! What a rockstar! 🙌🏼👏🏼👏🏼😍😍 https://t.co/Ia8sHHKQ4h
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @ElizaJaneLee: Congrats! Proud of you @AlisonMPease21!!! What a rockstar! 🙌🏼👏🏼👏🏼😍😍 https://t.co/Ia8sHHKQ4h
RT @BIDMCSurgery: Research by Dr. Ted A. James @BIDMCbreastsurg et al published in Feb. Annals of Surgical Oncology suggests #Oncotype DX t…
Congrats! Proud of you @AlisonMPease21!!! What a rockstar! 🙌🏼👏🏼👏🏼😍😍
Research by Dr. Ted A. James @BIDMCbreastsurg et al published in Feb. Annals of Surgical Oncology suggests #Oncotype DX testing could help identify patients most suited for #neoadjuvant chemotherapy and should be considered in the decision-making process.
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @Jad_Sattar: Quite amazing how the management of breast cancer is ever-changing! #OncotypeDX https://t.co/P7CuSGncdf
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @Jad_Sattar: Quite amazing how the management of breast cancer is ever-changing! #OncotypeDX https://t.co/P7CuSGncdf
RT @Jad_Sattar: Quite amazing how the management of breast cancer is ever-changing! #OncotypeDX https://t.co/P7CuSGncdf
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
Quite amazing how the management of breast cancer is ever-changing! #OncotypeDX
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT SocSurgOnc RT AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/zrONL69Z6r McMastersKelly SocSurgOnc
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
RT @AnnSurgOncol: FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tH…
FEBRUARY ISSUE: #OncotypeDX® Recurrence Score as a Predictor of Response to #NeoadjuvantChemotherapy. https://t.co/UJ60tHpsAw @McMastersKelly @SocSurgOnc
RT @BigDognMilton: Know your score to never miss a 26. https://t.co/IUStQa3S9R
Know your score to never miss a 26.
RT @kristinrojasmd: #Oncotype Dx @GenomicHealth to help guide preoperative #BreastCancer treatment, glad to see more validation for this…
RT @kristinrojasmd: #Oncotype Dx @GenomicHealth to help guide preoperative #BreastCancer treatment, glad to see more validation for this…
Agree! Be careful how you incorporate this in your practice as data is still emerging.
#Oncotype Dx @GenomicHealth to help guide preoperative #BreastCancer treatment, glad to see more validation for this practice #chemotherapy #BreastSurgery #BCSM #BreastCancer #MaimoBreastTeam https://t.co/t8zKdBFmXU
RT @BIDMCbreastsurg: We found that Oncotype DX testing could help identify patients best suited for neoadjuvant chemotherapy. @AnnSurgOnco…
We found that Oncotype DX testing could help identify patients best suited for neoadjuvant chemotherapy. @AnnSurgOncol #ClinicalResearch https://t.co/XSie7tO8Jn